Ignite Creation Date:
2025-12-25 @ 3:13 AM
Ignite Modification Date:
2026-01-11 @ 4:49 PM
Study NCT ID:
NCT03373305
Status:
WITHDRAWN
Last Update Posted:
2019-04-30
First Post:
2017-11-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
Sponsor:
City of Hope Medical Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | CD30-Positive Neoplastic Cells Present | View |
| None | Folliculotropic Mycosis Fungoides | View |
| None | Recurrent Mycosis Fungoides | View |
| None | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Refractory Mycosis Fungoides | View |
| None | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Sezary Syndrome | View |
Keywords: